The platinum-based drugs, cisplatin, carboplatin, and oxaliplatin, comprise the first-line defense against a number of different cancer types. Despite their widespread use, these agents suffer from several key limitations that negatively affect patient outcome and quality of life. For example, these drugs give rise to toxic side effects and are susceptible to drug resistance mechanisms in cancer cells, properties that ultimately decrease their therapeutic efficacy. Additionally, these platinum compounds cannot be readily imaged in vitro or in vivo. In this presentation, we will present our implementation of novel rhenium anticancer agents as a strategy to overcome the limitations of the conventional platinum-based anticancer drugs.  We find that these compounds are not cross-resistant with and are less toxic than cisplatin. Furthermore, the rich spectroscopic properties of these rhenium compounds are amenable to direct in vitro and in vivo imaging. Collectively, these results indicate that this class of rhenium compounds represents an important class of anticancer agents.<br/>

Rhenium as an alternative to platinum for the treatment of cancer

256th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.